A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population

Certolizumab pegol (CZP) is a PEGylated Fc-free tumor necrosis factor (TNF) inhibitor antibody approved for use in the treatment of rheumatoid arthritis (RA), Crohn’s disease, psoriatic arthritis, axial spondyloarthritis and psoriasis. In a clinical trial of patients with severe RA, CZP improved dis...

Descripción completa

Detalles Bibliográficos
Autores principales: White, Ian R., Kleinstein, Sarah E., Praet, Christophe, Chamberlain, Chris, McHale, Duncan, Maia, Jessica M., Xie, Pingxing, Goldstein, David B., Urban, Thomas J., Shea, Patrick R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004786/
https://www.ncbi.nlm.nih.gov/pubmed/35413058
http://dx.doi.org/10.1371/journal.pone.0261165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004786/
https://www.ncbi.nlm.nih.gov/pubmed/35413058
http://dx.doi.org/10.1371/journal.pone.0261165

Ejemplares similares